318 related articles for article (PubMed ID: 18677207)
21. [Significance of PET and integrated PET/CT in the diagnostics of occult primary tumors].
Schneider K; Hrasky A; Aschoff P; Bihl H; Hagen R
Laryngorhinootologie; 2006 Nov; 85(11):819-23. PubMed ID: 16612756
[TBL] [Abstract][Full Text] [Related]
22. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G
Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492
[TBL] [Abstract][Full Text] [Related]
23. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
Karantanis D; O'Neill BP; Subramaniam RM; Peller PJ; Witte RJ; Mullan BP; Wiseman GA
Clin Nucl Med; 2007 Apr; 32(4):271-4. PubMed ID: 17413571
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
[TBL] [Abstract][Full Text] [Related]
25. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis.
Kwee TC; Kwee RM
Eur Radiol; 2009 Mar; 19(3):731-44. PubMed ID: 18925401
[TBL] [Abstract][Full Text] [Related]
26. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
27. FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma.
Deantonio L; Beldì D; Gambaro G; Loi G; Brambilla M; Inglese E; Krengli M
Radiat Oncol; 2008 Sep; 3():29. PubMed ID: 18801181
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary.
Wang G; Wu Y; Zhang W; Li J; Wu P; Xie C
J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557
[TBL] [Abstract][Full Text] [Related]
29. 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis.
Zhu L; Wang N
Surg Oncol; 2013 Sep; 22(3):190-4. PubMed ID: 23849685
[TBL] [Abstract][Full Text] [Related]
30. Occult cancer detected by positron emission tomography/computed tomography image fusion.
Watanabe S; Tanaka D; Nakamura Y; Kariatsumari K; Fukumori K; Ohkubo J; Sakata R; Takagi K
Anticancer Res; 2005; 25(1B):459-61. PubMed ID: 15816612
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.
Cwikla JB; Nasierowska-Guttmejer A; Jeziorski KG; Cichocki A; Zgliczynski W; Stepień K; Seklecka N; Durlik M; Malkowski B; Walecki J
Neuro Endocrinol Lett; 2007 Dec; 28(6):789-800. PubMed ID: 18063942
[TBL] [Abstract][Full Text] [Related]
32. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases.
Huguet EL; Old S; Praseedom RK; Balan KK; Gibbs P; Jamieson NV
Hepatogastroenterology; 2007 Sep; 54(78):1667-71. PubMed ID: 18019690
[TBL] [Abstract][Full Text] [Related]
33. Considerations for generic oncology FDG-PET/CT protocol preparation in drug development.
Hallett WA; Maguire RP; McCarthy TJ; Schmidt ME; Young H
IDrugs; 2007 Nov; 10(11):791-6. PubMed ID: 17968761
[TBL] [Abstract][Full Text] [Related]
34. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
35. Intensity of FDG uptake is not everything: synchronous liposarcoma and fibrous dysplasia in the same patient on FDG PET-CT imaging.
Charest M; Singnurkar A; Hickeson M; Novales JA; Derbekyan V
Clin Nucl Med; 2008 Jul; 33(7):455-8. PubMed ID: 18580228
[TBL] [Abstract][Full Text] [Related]
36. 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease.
Ansquer C; Hervouët T; Devillers A; de Guibert S; Gastinne T; Le Gouill S; Garin E; Moreau A; Kraeber-Bodéré F; Lamy T
Haematologica; 2008 Jan; 93(1):128-31. PubMed ID: 18166797
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer.
Newbold KL; Partridge M; Cook G; Sharma B; Rhys-Evans P; Harrington KJ; Nutting CM
Acta Oncol; 2008; 47(7):1229-36. PubMed ID: 18661420
[TBL] [Abstract][Full Text] [Related]
38. PET/CT in pediatric oncology.
Samuel AM
Indian J Cancer; 2010; 47(4):360-70. PubMed ID: 21131747
[TBL] [Abstract][Full Text] [Related]
39. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis.
Mghanga FP; Lan X; Bakari KH; Li C; Zhang Y
Clin Breast Cancer; 2013 Aug; 13(4):271-9. PubMed ID: 23714689
[TBL] [Abstract][Full Text] [Related]
40. Desmoplastic melanoma: true positive and false negative findings on F-18 FDG-PET/CT.
Roarke MC; Nguyen BD; Pockaj BA
Clin Nucl Med; 2008 Aug; 33(8):562-4. PubMed ID: 18645380
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
